NDLI: Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.

Please wait, while we are loading the content...

Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.

Association between use of multiple psychoactive medicines and hospitalization for falls: retrospective analysis of a large healthcare claim database.

Safety signal detection: the relevance of literature review.

Performance of the standardised MedDRA® queries for case retrieval in the French spontaneous reporting database.

Readability assessment of package inserts of biological medicinal products from the European medicines agency website.

Pharmacists in pharmacovigilance: can increased diagnostic opportunity in community settings translate to better vigilance?

Year: 2014 Volume: 37 Issue: 6

Year: 2014 Volume: 37 Issue: 5

Year: 2014 Volume: 37 Issue: 4

Year: 2014 Volume: 37 Issue: 3

Year: 2014 Volume: 37 Issue: 2

Year: 2014 Volume: 37 Issue: 1

Year: 2014 Volume: 37 Issue: Supplementary 1

Year: 2013 Volume: 36

Year: 2012 Volume: 35

Year: 2011 Volume: 34

Year: 2010 Volume: 33

Year: 2009 Volume: 32

Year: 2008 Volume: 31

Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Chou, Hsin-Chun Chen, Wen-Wen Hsiao, Fei-Yuan
Spatial Coverage	Taiwan
Description	Country affiliation: Taiwan Author Affiliation: Chou HC ( Taiwan Drug Relief Foundation, Taipei, Taiwan.)
Abstract	BACKGROUND: Concern about an increasing risk of acute pancreatitis associated with incretin-based drugs, including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 analogs, has emerged recently. OBJECTIVE: This nested case-control study examined the association between the use of DPP-4 inhibitors and acute pancreatitis using Taiwan's National Health Insurance Research Database. METHODS: From a study cohort of patients with type 2 diabetes mellitus, we identified 1,957 acute pancreatitis cases (patients who had been admitted with a diagnosis of acute pancreatitis) and 7,828 age-, sex-, and cohort entry year-matched controls between 2000 and 2011. Multivariate conditional regression models were used to estimate the association between the use of DPP-4 inhibitors and acute pancreatitis. Sensitivity analyses were conducted by varying the definitions of timing of exposure to DPP-4 inhibitors. RESULTS: The risks of acute pancreatitis among current and past users of DPP-4 inhibitors were comparable with those of non-users (current users: adjusted odds ratio (aOR) 1.04; 95% CI [0.89-1.21]; past users: aOR 1.61 [0.93-2.77]). Similar results were found in sensitivity analyses with various definitions of 'current users' of DPP-4 inhibitors. Nevertheless, the adjusted risk of acute pancreatitis was found to be increased significantly in patients with gallstone disease (aOR 5.89 [4.71-7.35]), alcohol-related disease (aOR 5.36 [4.05-7.08]), hypertriglyceridemia (aOR 1.80 [1.26-2.56]), pancreatic disease (aOR 17.29 [10.60-28.19]), and a higher Diabetes Complications Severity Index (DCSI) score (DCSI 3-4: aOR 1.49 [1.21-1.84]; DCSI≥5: aOR 1.32 [1.01-1.73]). CONCLUSIONS: This population-based study extends previous evidence by exploring the potential association between DPP-4 inhibitor use and the risk of acute pancreatitis in an ethnic Chinese type 2 diabetic cohort. We found that underlying diseases and severity of diabetes but not DPP-4 inhibitor use were associated with acute pancreatitis.
File Format	HTM / HTML
ISSN	01145916
Issue Number	7
Volume Number	37
e-ISSN	11791942
Journal	Drug Safety
Language	English
Publisher	Springer
Publisher Date	2014-07-01
Publisher Place	New Zealand (Aotearoa)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Toxicology Diabetes Mellitus, Type 2 Drug Therapy Dipeptidyl-peptidase Iv Inhibitors Adverse Effects Pancreatitis Chemically Induced Acute Disease Adolescent Adult Aged Case-control Studies Cohort Studies Comorbidity Data Interpretation, Statistical Databases, Factual Epidemiology Administration & Dosage Therapeutic Use Female Humans Male Middle Aged Risk Taiwan Young Adult Journal Article Research Support, U.s. Gov't, P.h.s.
Content Type	Text
Resource Type	Article
Subject	Toxicology Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.

Acute pancreatitis and type 2 diabetes mellitus: who is guilty?

Vildagliptin-induced acute pancreatitis.

Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?

Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis

Association of Meloxicam Use with the Risk of Acute Pancreatitis: A Case-Control Study.

Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study

Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.

Similar Documents

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.

Acute pancreatitis and type 2 diabetes mellitus: who is guilty?

Vildagliptin-induced acute pancreatitis.

Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?

Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis

Association of Meloxicam Use with the Risk of Acute Pancreatitis: A Case-Control Study.

Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study

Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.